Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Physical Sciences, Biochemical Research Methods, Chemistry, Medicinal, Chemistry, Analytical, Biochemistry & Molecular Biology, Pharmacology & Pharmacy, Chemistry, exendin-4, GLP-1 receptor, insulinoma, peptide receptor radionuclide therapy (PRRT), positron emission tomography (PET), single-photon emission computed tomography (SPECT), targeted photodynamic therapy (tPDT), theranostics, GLUCAGON-LIKE PEPTIDE-1, GLP-1 RECEPTOR, NEUROENDOCRINE TUMORS, PHOTODYNAMIC THERAPY, GA-68-DOTA-EXENDIN-4 PET/CT, RADIOLABELED PEPTIDES, RADIONUCLIDE THERAPY, CALCIUM STIMULATION, OCCULT INSULINOMA, KIDNEY UPTAKE, Animals, Diagnostic Imaging, Exenatide, Humans, Insulinoma, Photochemotherapy, 0305 Organic Chemistry, 1115 Pharmacology and Pharmaceutical Sciences, Medicinal & Biomolecular Chemistry, 3405 Organic chemistry

Abstract:

Insulinomas, neuroendocrine tumors arising from pancreatic beta cells, often show overexpression of the glucagon-like peptide-1 receptor. Therefore, imaging with glucagon-like peptide analog exendin-4 can be used for diagnosis and preoperative localization. This review presents an overview of the development and clinical implementation of exendin-based tracers for nuclear imaging, and the potential use of exendin-4 based tracers for optical imaging and therapeutic applications such as peptide receptor radionuclide therapy or targeted photodynamic therapy.